Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Cellectis    ALCLS   FR0010425595

CELLECTIS

(ALCLS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Growth Paris
11/24/2020 11/25/2020 11/26/2020 11/27/2020 11/30/2020 Date
18.58(c) 18.32(c) 19.46(c) 19.66(c) 20.3(c) Last
89 608 131 922 128 868 84 706 153 317 Volume
+2.31% -1.40% +6.22% +1.03% +3.26% Change
More quotes
Financials
Sales 2020 61,9 M 73,8 M 73,8 M
Net income 2020 -70,3 M -83,9 M -83,9 M
Net cash position 2020 198 M 236 M 236 M
P/E ratio 2020 -6,52x
Yield 2020 -
Sales 2021 66,3 M 79,1 M 79,1 M
Net income 2021 -106 M -127 M -127 M
Net cash position 2021 118 M 140 M 140 M
P/E ratio 2021 -6,76x
Yield 2021 -
Capitalization 863 M 1 031 M 1 028 M
EV / Sales 2020 10,7x
EV / Sales 2021 11,2x
Nbr of Employees 259
Free-Float 83,2%
More Financials
Company
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing... 
More about the company
Notations Surperformance© of Cellectis
Trading Rating : Investor Rating :
More Ratings
All news about CELLECTIS
11/18CELLECTIS : FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis' Pro..
AQ
11/17CELLECTIS : FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis' Pro..
AQ
11/17CELLECTIS : FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis' Pro..
AQ
11/17FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis' Product Cand..
GL
11/17CALYXT, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
11/17CELLECTIS : Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice Presid..
AQ
11/16CELLECTIS : Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice Presid..
AQ
11/16CELLECTIS : Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice Presid..
AQ
11/16Cellectis Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice Presi..
GL
11/13CELLECTIS : Corporate Presentation November 2020
PU
11/06CELLECTIS : Provides Business Update and Reports Financial Results for Third Qua..
AQ
11/06CELLECTIS : American Society of Hematology (ASH) Abstract Shows Initial Anti-Leu..
AQ
11/05CALYXT : 3Q Earnings Snapshot
AQ
11/05CALYXT : Management's Discussion and Analysis of Financial Condition and Results..
AQ
11/05CELLECTIS : Provides Business Update and Reports Financial Results for Third Qua..
AQ
More news
News in other languages on CELLECTIS
11/18CELLECTIS : la FDA autorise la reprise de l'essai clinique MELANI-01
11/18Les marchés attendent leur shoot de vaccin et de liquidités
11/18EN DIRECT DES MARCHES : Thales, Sanofi, Engie, Lyxor, Ubisoft, OSE Immuno, Boein..
11/17CELLECTIS : La FDA autorise la reprise de l'essai clinique MELANI-01 évaluant le..
11/13La différence entre un vaccin et une baguette magique
More news
Stock Trading Strategies
CELLECTIS - 04/14
Is the distribution phase coming to an end ?
BUY
More Stock Trading Analysis
Chart CELLECTIS
Duration : Period :
Cellectis Technical Analysis Chart | ALCLS | FR0010425595 | MarketScreener
Technical analysis trends CELLECTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 20,50 €
Last Close Price 20,30 €
Spread / Highest target 0,99%
Spread / Average Target 0,99%
Spread / Lowest Target 0,99%
EPS Revisions
Managers
NameTitle
André Choulika Chief Executive Officer
Jean-Pierre Garnier Non-Executive Chairman
Eric Dutang Chief Financial Officer
Philippe Duchateau Chief Scientific Officer
Francisco J. Esteva Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
CELLECTIS25.38%999
MODERNA, INC.549.44%50 267
LONZA GROUP AG56.23%45 319
CELLTRION, INC.82.04%40 460
IQVIA HOLDINGS INC.9.26%32 365
SEAGEN INC.48.01%30 493